SAN ANTONIO--(BUSINESS WIRE)--America Stem Cell, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to ASC-101 to improve homing to bone marrow (treatment of myeloablation) in patients receiving hematopoietic stem cell transplantation.
